Key result
SGLT2i and GLP1-RAs confer CV protection in T2D via anti-inflammatory and anti-oxidative pathways beyond glucose lowering.
Why the study?
Cardiovascular benefits of SGLT2i and GLP1-RAs in T2DM cannot be exclusively attributed to glycemic control, prompting interest in their molecular mechanisms against inflammation and oxidative stress.
Do SGLT2i and GLP1-RAs provide cardiovascular protection through anti-inflammatory and anti-oxidative effects in patients with Type 2 diabetes?
Do SGLT2i and GLP1-RAs provide cardiovascular protection through anti-inflammatory and anti-oxidative effects in patients with Type 2 diabetes?
SGLT2i and GLP1-RAs offer cardiovascular protection in T2DM patients via anti-inflammatory and anti-oxidative pathways beyond glycemic control.
Answers are grounded in this paper and cite their sources.
Reinforces pleiotropic mechanisms of SGLT2i and GLP-1RAs; leaves open their weighting in outcome trials.
Type 2 diabetes mellitus (T2DM) is a chronic and progressive dysmetabolic condition related to several complications, including cardiovascular disease, whose incidence is increasing worldwide. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) are two new molecules recently made available for T2DM treatment, with the aim of reducing hyperglycemia. Recent evidence has also highlighted that in addition to the glucose-lowering action, both SGLT2i and GLP1-RAs ensure significant beneficial effects in reducing cardiovascular damage in T2DM patients. Interestingly, these benefits cannot be exclusively attributed to the improved glycemic control. Indeed, experimental and clinical studies have shed light on the protective role of SGLT2i and GLP-1RAs against inflammation and oxidative stress, especially in the heart and vasculature. In our review we elucidate the potential cardiovascular benefits provided by SGLT2i and GLP1-RAs to T2DM subjects by exploring the molecular pathways involved in the process of cardiovascular protection.
No takes yet. Share an insight, caveat, or question.
Marcon et al. (2025) conducted a review in Type 2 diabetes mellitus (T2DM). SGLT2i and GLP1-RAs was evaluated. SGLT2i and GLP1-RAs provide cardiovascular protection in type 2 diabetes patients through anti-inflammatory and anti-oxidative molecular pathways beyond their glucose-lowering effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: